Incorporating upper motor neuron health in ALS drug discovery

Ina Dervishi, P. Hande Ozdinler*

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Amyotrophic lateral sclerosis (ALS) is a complex disease, that affects the motor neuron circuitry. After consecutive failures in clinical trials for the past 20 years, edaravone was recently approved as the second drug for ALS. This generated excitement in the field revealed the need to improve preclinical assays for continued success. Here, we focus on the importance and relevance of upper motor neuron (UMN) pathology in ALS, and discuss how incorporation of UMN survival in preclinical assays will improve inclusion criteria for clinical trials and expedite the drug discovery effort in ALS and related motor neuron diseases.

Original languageEnglish (US)
Pages (from-to)696-703
Number of pages8
JournalDrug Discovery Today
Volume23
Issue number3
DOIs
StatePublished - Mar 2018

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Incorporating upper motor neuron health in ALS drug discovery'. Together they form a unique fingerprint.

  • Cite this